bs-23966R [Primary Antibody]
Smad4
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: SMAD4

Immunogen Range: 451-552/552


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 4089

Swiss Prot: Q13485

Source: KLH conjugated synthetic peptide derived from human Smad4

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for syngernistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.

Size: 100ul

Concentration: 1mg/ml

Applications: WB(1:300-5000)
ELISA(1:500-1000)

Predicted Molecular Weight: 60


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Dog
Cow
Sheep
Pig
Horse
Chicken
Rabbit
Zebrafish

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Genghua Chen. et al. Bulk and single-cell alternative splicing analyses reveal roles of TRA2B in myogenic differentiation. CELL PROLIFERAT. 2023 Sep;:e13545Read more>>
VALIDATION IMAGES

Lane 1: Human K562 cell lysates; Lane 2: Human Hela cell lysates; Lane 3: Human Jurkat cell lysates; Lane 4: Human HL-60 Cell lysates probed with Smad4 Polyclonal Antibody, Unconjugated (bs-23966R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.